Navigation Links
Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
Date:3/27/2009

l.

The trial's sponsors and Principal Investigators are now seeking approval to broaden the study to include dialysis patients as well as pre-dialysis patients. More information on this will be announced as developments proceed.

The Company's active discussions with major potential strategic partners have expanded since the announcement in February, with additional companies having expressed interest in one or more applications.

NOTES TO EDITORS:

Medgenics, Inc. is a clinical-stage biopharmaceutical company developing its unique tissue-based Biopump platform technology to provide sustained-action protein therapy for the treatment of a range of chronic diseases.

Medgenics currently has two products in development based on this technology:

  • EPODURE - producing erythropoietin (EPO) to treat anemia
  • INFRADURE - producing interferon-alpha (IFN-a) to treat Hepatitis-C

The Company's ongoing Phase I/II clinical trial for EPODURE in anemic patients continues to demonstrate proof of concept of the Biopump. Designed to produce and deliver a therapeutic dose of EPO steadily for up to six months or more, EPODURE Biopumps are already maintaining effective anemia treatment for more than 5 months in earliest patients in the ongoing study, even with low dose administered.

Medgenics intends to develop its innovative products and bring them to market via multiple strategic partnerships with major pharmaceutical and/or medical device companies, starting with EPODURE and INFRADURE.

Medgenics plans to raise the requisite funds during 2009 to enable it to follow the current trial of EPODURE with a Phase IIb clinical trial in the US starting in 2010, and in addition, to commence a Phase I/II trial of INFRADURE in Hepatitis-C patients in Israel also during 20
'/>"/>

SOURCE Medgenics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medgenics Announces Positive Data From Phase I/II Clinical Trial of EPODURE Treatment of Anemia in Chronic Kidney Disease
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 Revenue and earnings above the ... and development In the past 2013/14 fiscal year ... percent to EUR 4.287 billion (last year: EUR 4.190 billion) ... to EUR 360 million. "Overall, 2013/14 was a successful fiscal ... , President and CEO of Carl Zeiss AG. "Thanks to ...
(Date:12/17/2014)... , The new ... of information concerning the biopharmaceutical Group,s national and international clinical ... to the recently launched institutional website that is receiving accolades ... by a new chapter in the fascinating story of Drug ... and panoramic hub on the world of clinical research, ranging ...
(Date:12/17/2014)... HOUSTON , Dec. 17, 2014 ... Autism Approved ( http://bit.ly/1382OkS ) program seal ... autism community. The program highlights medical practices, materials ... considered "autism-community friendly." Children affected by ... that can be exacerbated by ingredients found in ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3
... 2, 2011 The Center for Radiation Therapy of ... patients in the Los Angeles area, has been awarded ... the result of a recent review by the American ... Radiation Oncology (ASTRO). Radiation oncology (radiation ...
... Va., March 2, 2011 Insmed Incorporated (Nasdaq: ... the one-for-10 reverse stock split of Insmed,s Common Stock ... 2, 2011, after the State Corporation Commission of the ... of Incorporation to effect the reverse stock split.  The ...
Cached Medicine Technology:The Center for Radiation Therapy of Beverly Hills Earns ACR-ASTRO Accreditation 2The Center for Radiation Therapy of Beverly Hills Earns ACR-ASTRO Accreditation 3One-for-10 Reverse Stock Split of Insmed Common Stock Becomes Effective 2
(Date:12/20/2014)... News) -- The holidays can be anything but joyous ... trees, scented candles and other allergy triggers. "The ... have been packed away in dank basements or dusty ... patients," Dr. Rachna Shah, an affiliate faculty member at ... Loyola news release. Shah, who is also an ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 The Doctor’s Office ... for the better part of a decade. They’ve treated ... a better, faster healthcare alternative to the Paramus ... announce three new additions to their staff of top-notch board ... Jill Zeiger MD. These new doctors will work ...
(Date:12/20/2014)... New York, New York (PRWEB) December 20, 2014 ... ) continue to move forward in U.S. ... a new study which suggests that children treated ... prolactin, a hormone linked to breast development and ... Psychopharmacology, looked at 34 children and adolescents who ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 The aftermath of ... quite a stir, not only in Hollywood, but worldwide. ... 18th , the ripples of that attack are starting a ... jobs at risk. But they are not the only ... could be in for some embarrassing times ahead, agents and ...
(Date:12/20/2014)... Developers of FCPX 3rd Party ... for Final Cut Pro X entitled TranSlice Volume 5 ... users to create hand drawn text animations without having ... of Pixel Film Studios. “TranSlice Volume 5 was professionally ... easy to use interface.” , TranSlice Volume 5 from ...
Breaking Medicine News(10 mins):Health News:Holiday Trimmings Can Trigger Allergies 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2
... (fight against inflammation) that are 10, 000 times more ... nimusulide and aspirin have been developed and patented by ... Medical Sciences (AIIMS), situated in New Delhi, India, have ... about 10,000 times better than the commonly used pain ...
... is threatening to cause a major upheaval to the ... spread, according to the Coordinating Minister// for People’s Welfare, ... expressed fears on the dwindling poultry industry and a ... to the pandemic. ,The consequences would be ...
... the magnets that are sold in the market does not ... problems//. Magnet that are advertised over the net and sold ... value. ,Magnets are sought after by the successful ... it is all bogus. The research was done by ...
... not aware about dugs and its effect till 1980. But ... is a lot of information available from varied sources// such ... ,The information that is available in these formats has to ... made accessible. This was done by Dr. David Wishart, faculty ...
... symposium on Stem cell Research and Therapy was conducted ... was organized by LifeCell//, a pioneer in stem cell ... Research Institute, one of the reputed medical institutions in ... hematologist, CMC, Vellore, headed the symposium. Following a small ...
... Woodruff (R) said he had filed a bill (HB 1096) that ... would endanger the life or health of the mother. ... a Class C felony, carrying a two- to eight-year prison sentence. ... a state must pass a law and then appeal it to ...
Cached Medicine News:Health News:Does Magnet Therapy Posses Healing Powers? 2Health News:Drug Database Goes On Air 2Health News:Stem Cell Research - Changing Wishes to Possibilities and Possibilities to Reality 2
... The TL-100 uses technology that takes ... by automatically detecting and reading them. It ... recording the results, mark lenses as you ... contact lenses. Easy to use, the TL-100 ...
... The Kowa RC-XV3 camera is ... The automatic exposure system, ... sensitivity, the 2.5~300ws watt indication ... handling are the basic features ...
FF 450plus fundus camera for 35mm photography. Upgradeable basic instrument for brilliant image quality....
The new TRC-NW6 non-mydriatic retinal camera is the ideal instrument for the growing market in telemedicine and diabetic screening....
Medicine Products: